M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Longitudinal Assessment of Arthralgia and Related Symptoms in Breast Cancer Patients Receiving Aromatase Inhibitors

Not Applicable

Terminated

Conditions: Breast Cancer

Interventions: Behavioral: Questionnaire
Other: Phone Calls

First Posted Date: 2008-08-21

Last Posted Date: 2020-01-02

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 102

Registration Number: NCT00738998

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Relaxation and Heart Rate Variability

Not Applicable

Completed

Conditions: Cancer

Interventions: Other: Guided Relaxation

First Posted Date: 2008-08-15

Last Posted Date: 2011-12-19

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 20

Registration Number: NCT00735618

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Phase I Portion of Phase I/II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma

Phase 1

Terminated

Conditions: Glioblastoma
Gliosarcoma

Interventions: Drug: Temozolomide
Radiation: Radiation
Drug: Sorafenib

First Posted Date: 2008-08-14

Last Posted Date: 2018-11-09

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 18

Registration Number: NCT00734526

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Hepatic Arterial Infusion (HAI) of Abraxane

Phase 1

Completed

Conditions: Liver Cancer
Advanced Cancers
Solid Tumors

Interventions: Drug: HAI Abraxane
Procedure: Hepatic Artery Catheter
Drug: IV Abraxane

First Posted Date: 2008-08-12

Last Posted Date: 2016-02-05

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 64

Registration Number: NCT00732836

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Methadone, Morphine, or Oxycodone in Treating Pain in Patients With Cancer

Not Applicable

Terminated

Conditions: Chronic Myeloproliferative Disorders
Brain and Central Nervous System Tumors
Leukemia
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Neoplasms
Pain
Precancerous Condition
Unspecified Adult Solid Tumor, Protocol Specific
Lymphoma
Lymphoproliferative Disorder

Interventions: Drug: methadone hydrochloride
Drug: morphine sulfate
Drug: oxycodone hydrochloride

First Posted Date: 2008-08-01

Last Posted Date: 2020-09-24

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 1

Registration Number: NCT00726830

Locations: 🇺🇸
Palmetto Hematology Oncology, PC at Gibbs Regional Cancer Center, Spartanburg, South Carolina, United States
🇺🇸
M. D. Anderson Cancer Center at University of Texas, Houston, Texas, United States

Magnetic Resonance Temperature Imaging & Imaging-Guided Laser Induced Thermal Therapy for Treatment of Metastatic Brain Tumors

Not Applicable

Terminated

Conditions: Brain Tumor

Interventions: Procedure: Visualase® Thermal Therapy System

First Posted Date: 2008-07-23

Last Posted Date: 2012-10-11

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 6

Registration Number: NCT00720837

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Pre-Surgical Sutent in Renal Cell Carcinoma (RCC)

Phase 2

Active, not recruiting

Conditions: Renal Cell Carcinoma

Interventions: Drug: Sunitinib
Procedure: Nephrectomy

First Posted Date: 2008-07-15

Last Posted Date: 2024-10-04

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 50

Registration Number: NCT00715442

Locations: 🇺🇸
Baylor College of Medicine, Houston, Texas, United States
🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

8-Chloro-Adenosine in Chronic Lymphocytic Leukemia

Phase 1

Completed

Conditions: Leukemia
Chronic Lymphocytic Leukemia

Interventions: Drug: 8-Chloro-Adenosine

First Posted Date: 2008-07-14

Last Posted Date: 2016-10-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 11

Registration Number: NCT00714103

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Docetaxel, Cisplatin and Fluorouracil in Treating Patients with Previously Untreated Stage II-IV Nasal Cavity and Paranasal Sinus Cancer

Phase 2

Active, not recruiting

Conditions: Locally Advanced Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma
Nasal Cavity and Paranasal Sinus Poorly Differentiated Carcinoma
Sinonasal Undifferentiated Carcinoma
Stage II Nasal Cavity and Paranasal Sinus Cancer AJCC V8
Stage III Nasal Cavity and Paranasal Sinus Cancer AJCC V8
Stage IVA Nasal Cavity and Paranasal Sinus Cancer AJCC V8
Stage IVB Nasal Cavity and Paranasal Sinus Cancer AJCC V8

Interventions: Drug: Carboplatin
Other: Chemoradiotherapy
Drug: Cisplatin
Procedure: Definitive Surgical Resection
Drug: Docetaxel
Drug: Fluorouracil
Procedure: Quality-of-Life Assessment
Radiation: Radiation Therapy

First Posted Date: 2008-06-30

Last Posted Date: 2024-12-04

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 31

Registration Number: NCT00707473

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Continuous Glucose Monitoring in Critically Ill

Not Applicable

Terminated

Conditions: Diabetes

Interventions: Device: Guardian® blood-sugar monitoring device

First Posted Date: 2008-06-30

Last Posted Date: 2020-03-23

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 6

Registration Number: NCT00707434

Locations: 🇺🇸
The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States
🇺🇸
University of Texas Medical Branch at Galveston, Galveston, Texas, United States
🇺🇸
University of Texas Health Science Center at Houston, Houston, Texas, United States

and more 3 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy